|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1998-5-28
|
|
pubmed:abstractText |
Our objective was to determine the clinical activity, toxicity, and immunological effects of active immunotherapy using UVB-irradiated (UVR) autologous tumor (AT) cells plus adjuvant DETOX in metastatic melanoma patients. Eligibility included nonanergic patients fully recovered after resection of 5 or more grams of metastatic melanoma. Treatment consisted of intradermal injections of 10(7) UVR-AT plus 0.25 ml of DETOX every 2 weeks x 6, then monthly. Peripheral blood mononuclear cells (PBMCs) were harvested for cytotoxicity assays, and skin testing was performed for delayed-type hypersensitivity (DTH) determinations before the first, fourth, seventh, and subsequent treatments. Forty-two patients were treated, 18 in the adjuvant setting and 24 with measurable disease. Among the latter group, there were two durable responses in soft-tissue sites and in a bone metastasis. Treatment was well tolerated. Thirty-five patients were assessable for immunological parameters; 10 of these patients, including the 2 responders, demonstrated early induction of PBMC cytotoxicity against AT cells that persisted up to 10 months on treatment before falling to background levels. In five of seven patients, the fall-off heralded progressive disease. Late induction of a weak DTH reaction to AT cells was observed in eight patients. Active immunotherapy with UVR-AT + DETOX had modest but definite clinical activity in advanced melanoma. The induction of both PBMC cytotoxicity and DTH reactivity to AT cells supported a specific systemic immune effect of treatment, although the former more closely followed disease course in this study.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BalchC MCM,
pubmed-author:BedikianA YAY,
pubmed-author:BenjaminR SRS,
pubmed-author:BuzaidA CAC,
pubmed-author:DonawhoCC,
pubmed-author:EtonOO,
pubmed-author:GiananM AMA,
pubmed-author:ItohKK,
pubmed-author:KharkevitchD DDD,
pubmed-author:LeaJ AJA,
pubmed-author:LeghaS SSS,
pubmed-author:MansfieldP FPF,
pubmed-author:PapadopoulosN ENE,
pubmed-author:PlagerCC,
pubmed-author:PrideM WMW,
pubmed-author:RossM IMI
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
619-27
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:9533529-Adjuvants, Immunologic,
pubmed-meshheading:9533529-Adult,
pubmed-meshheading:9533529-Aged,
pubmed-meshheading:9533529-Aged, 80 and over,
pubmed-meshheading:9533529-Antigens, CD,
pubmed-meshheading:9533529-Bone Neoplasms,
pubmed-meshheading:9533529-Cancer Vaccines,
pubmed-meshheading:9533529-Cytoskeletal Proteins,
pubmed-meshheading:9533529-Cytotoxicity, Immunologic,
pubmed-meshheading:9533529-Drug Combinations,
pubmed-meshheading:9533529-Female,
pubmed-meshheading:9533529-Humans,
pubmed-meshheading:9533529-Hypersensitivity, Delayed,
pubmed-meshheading:9533529-Immunity, Active,
pubmed-meshheading:9533529-Immunoglobulin G,
pubmed-meshheading:9533529-Immunotherapy,
pubmed-meshheading:9533529-Lipid A,
pubmed-meshheading:9533529-Male,
pubmed-meshheading:9533529-Melanoma,
pubmed-meshheading:9533529-Middle Aged,
pubmed-meshheading:9533529-Neoplasm Staging,
pubmed-meshheading:9533529-Skin Neoplasms,
pubmed-meshheading:9533529-Soft Tissue Neoplasms,
pubmed-meshheading:9533529-Survival Rate,
pubmed-meshheading:9533529-Time Factors,
pubmed-meshheading:9533529-Ultraviolet Rays
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
|
|
pubmed:affiliation |
Department of Melanoma/Sarcoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.
|
